Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FhHDM-1
- Development stage
- Preclinical
- Lead developer
- University of Technology Sydney
- Modality
- Peptides
- Administration
- Intraperitoneal, Intravenous
01
Overview
FhHDM-1 (Fasciola hepatica helminth defence molecule 1) is a parasite-derived 68-mer cathelicidin-like peptide originally isolated from the excretory-secretory products of the liver fluke *Fasciola hepatica*. It is being developed for the prevention and treatment of autoimmune and inflammatory diseases, including type 1 diabetes and multiple sclerosis. FhHDM-1 acts by modulating macrophage function, preventing endolysosomal acidification, and inhibiting NLRP3 inflammasome activation and subsequent IL-1β secretion. Additionally, FhHDM-1 localizes to the pancreas where it directly promotes pancreatic beta cell survival and function by activating the PI3K/Akt signaling pathway, protecting them from cytokine-induced apoptosis without inducing proliferation.
- Other names
- Fasciola hepatica helminth defence molecule 1Fasciola hepatica helminth defense molecule 1FhHDM1FhHDM-1FhHDM 1
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)IGF-1R (Insulin-like growth factor 1 receptor)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)CTSB (Cathepsin B)V-ATPase (Vacuolar-type H+-ATPase)
Beyond the preview
Go deeper on FhHDM-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FhHDM-1.